Business
Jaguar Health Reports First Quarter 2024 Financial Results
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023
About this update from Jaguar Health, Inc.
[{"type":"text","content":"The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 millionTop line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaJaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription productREMINDER: Jaguar to host investor webcast Tuesday, May 14th at 8:30 a.m. Eastern regarding Q1 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today reported consolidated first-quarter 2024 financial results and provided Company updates.The combined net revenue for the Company's crofelemer prescription products, Mytesi® and Canalevia®-CA1, and the Company's non-prescription products was approximately $2.4 million in the first quarter of 2024, representing an increase of approximately 20% over the combined net revenue in the first quarter of 2023, which totaled approximately $2.0 million, and an increase of approximately 4% over the combined net revenue in the fourth quarter of 2023, which totaled approximately $2.3 million.Lisa Conte, Jaguar's president and CEO, said, \"Our paramount near-term clinical activity is our phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea (CTD), an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. Top line results from this pivotal study are expected to be imminent.\"As announced, Jaguar signed an exclusive 5-year in-license agreement in April 2024 for the FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market. Jaguar is planning to begin the commercial launch in Q3 2024 for Gelclair.\"Gelclair is an FDA-approved prescription product and can be commercialized without any clinical development costs for Jaguar,\" added Conte. \"We are expanding our footprint beyond HIV-related supportive care to include cancer-related support...